再生医療の世界市場：製品、治療領域、地域別、2024年～2031年

再生医療市場の評価、2024年～2031年

がん、中枢神経疾患、その他のような蔓延する慢性疾患の抑制における予防医療と個別化医療の利点に関する一般市民の意識の高まりが、再生医療市場の成長可能性を後押ししています。Verified Market Researchのアナリストによると、再生医療市場は、2024年に評価された327億1,000万米ドルの収益を征服することにより、予測を超えて、2031年までに1,734億9,000万米ドルの評価に達すると推計されています。

高齢化人口の増加に伴う疾病負担の増加は、再生医療市場の主要な促進要因です。ヘルスケア情勢の変化という現在の動向は、時間の経過とともに拡大すると予想され、2024年から2031年にかけて23.19%のCAGRで市場が成長することを可能にしています。

再生医療市場定義/概要

再生医療は、身体が本来持っている治癒・修復能力を利用することに重点を置く先進的な医学の一分野です。正常な機能を回復させるために、損傷した組織や臓器に刺激を与えたり、置き換えたりする最新の手順を用います。重要な戦略のひとつは、幹細胞の活用です。幹細胞は、多様な細胞型に分化するユニークな能力を持っています。再生医療では、科学者や医師がこれらの細胞を用いて、怪我や病気、老化によって損傷した組織を修復したり、置き換えたりします。

さらに、心臓疾患や関節損傷の治療、皮膚の再生、さらには移植用の臓器の培養などは、再生医療の数ある応用例のほんの一部に過ぎないです。その目的は、身体に本来備わっている治癒能力を育み、多様な健康問題に対する独創的な解決策を提供することで、医療介入を変革することです。

慢性疾患の蔓延は再生医療の売上を急増させるか？

がん、心血管疾患、神経疾患などの有病率の上昇に伴い、根本的な原因に対処し、疾病の改善や治癒の可能性さえも提供する、際立った医療が求められています。その結果、慢性疾患の有病率が上昇し、再生医療市場の成長率を高める主要な要因となっています。

遺伝子編集、幹細胞工学、3Dバイオプリンティングにおける急速な進歩は、より効果的でオーダーメイドの医薬品の開発を加速させる。これらのブレークスルーは、治療可能な病気の種類を広げ、治療精度を向上させ、全体的な患者の転帰を改善し、再生医療を市場におけるヘルスケアの主流に押し上げます。

さらに、創薬の研究開発における政府の支援と資金提供の増加は、再生医療の拡大にとって極めて重要です。また、ベンチャーキャピタル、製薬企業、政府機関がこの種の医療の生産性を高めるために提供する資金援助も増加しています。これに加えて、製薬業界の財政的安定は、より迅速な臨床研究、より大規模な患者コホート、より迅速な市場浸透につながっており、これらすべてが再生医療市場の成長を後押ししています。

高い製造コストと複雑な製造工程は、再生医療市場にどのような影響を与えているのか？

細胞治療や遺伝子治療に関する安全性への懸念と相まって、規制制度が複雑であるため、認可プロセスには時間とコストがかかります。したがって、厳しい規制と長い承認プロセスが再生医療市場の成長を抑制する障壁となっています。

細胞・遺伝子治療には高い製造コストと複雑な製造手順が伴うため、再生医療市場は製造と拡張性の面でかなりの課題に直面しています。使用される生物学的成分の壊れやすい性質が課題に拍車をかけ、より高い費用と患者アクセスの制限をもたらします。

さらに、これらの治療法の高額な費用は患者のアクセスを制限し、ヘルスケアシステムを圧迫しています。未熟な償還政策と、高額な初期費用と再生医療の短期的データを考慮した保険会社の費用負担への消極性は、その採用を制限する主要な課題です。

目次

第1章 世界の再生医療市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• 検証
• プライマリーインタビュー
• データソース一覧

第4章 世界の再生医療市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 再生医療の世界市場：製品別

• 概要
• 治療薬
• 細胞療法
  • 幹細胞治療
  • 細胞移植
• 幹細胞治療製品
• 細胞免疫療法製品
• 遺伝子治療
• 組織工学

第6章 再生医療の世界市場：治療領域別

• 概要
• 腫瘍学
• 筋骨格系疾患
• 皮膚科・創傷治療
• 心血管疾患
• 眼科
• 神経学
• その他の用途

第7章 再生医療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • その他のラテンアメリカ
• 中東・アフリカ
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第8章 世界の再生医療市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略
• 企業の地域フットプリント
• 企業の産業フットプリント
• ACEマトリックス

第9章 企業プロファイル

• Johnson & Johnson
• Novartis
• Roche
• AbbVie
• Pfizer
• Vericel Corporation
• Cellular Dynamics International
• Editas Medicine
• Spark Therapeutics
• Bluebird bio

第10章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Regenerative Medicine Market Valuation - 2024-2031

Growing public awareness regarding the benefits of preventative and personalized medicine in curbing prevalent chronic diseases such as cancer, central nervous diseases, and others drives the growth potential of the Regenerative Medicine Market. According to the analyst from Verified Market Research, the Regenerative Medicine Market is estimated to reach a valuation of USD 173.49 Billion by 2031, over the forecast by subjugating the revenue of USD 32.71 Billion valued in 2024.

The rising burden of diseases among the growing aging population is a key driver of the Regenerative Medicine Market. The current trend of shifting healthcare landscape is expected to grow over time enabling the market to grow at aCAGR of 23.19% from 2024 to 2031.

Regenerative Medicine Market: Definition/ Overview

Regenerative medicine is an advanced branch of medicine that focuses on using the body's natural ability to heal and repair itself. It involves using modern procedures to stimulate or replace damaged tissues and organs to restore normal function. One important strategy is the utilization of stem cells, which have the unique capacity to differentiate into diverse cell types. In regenerative medicine, scientists and physicians use these cells to repair or replace damaged tissues caused by injury, disease, or aging.

Furthermore, treatments for heart problems and joint injuries, skin regeneration, and even the cultivation of organs for transplantation are just a few of the numerous applications for regenerative medicine. The aim is to transform medical interventions by fostering the body's inherent healing capacities and offering inventive resolutions for diverse health issues.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Prevalence of Chronic Illnesses Skyrocket the Sales of Regenerative Medicine?

The rising prevalence of conditions such as cancer, cardiovascular disease, and neurological disorders demands medicine that stands out by offering the potential for disease modification or even cure, addressing the root causes. As a result, the rising prevalence of chronic diseases poses a key driver resulting in a higher trajectory of growth in the Regenerative Medicine Market.

Rapid advancements in gene editing, stem cell engineering, and 3D bioprinting speed up the development of more effective and tailored medicines. These breakthroughs broaden the variety of treatable illnesses, improve treatment precision, and improve overall patient outcomes, propelling regenerative medicine to mainstream healthcare in the market.

Furthermore, growing government support and funding in the research and development of drug discovery are crucial for the expansion of regenerative medicine. There is also a rise in financial support offered by venture capitalists, pharmaceutical corporations, and government agencies in upsurging the productivity of this kind of medicine. In addition to this, financial stability in the pharmaceutical industry is leading to faster clinical studies, larger patient cohorts, and faster market penetration, all of which contribute to bolstering the growth of the Regenerative Medicine Market.

How are High Production Costs and Complex Manufacturing Processes Favoring the Regenerative Medicines Market?

The complexity of the regulatory systems, combined with safety concerns about cell and gene therapies, makes the authorization process lengthy and costly. Thus, stringent restrictions and lengthy approval processes are barriers restraining the growth of the Regenerative Medicine Market.

Due to the high production costs and intricate manufacturing procedures involved in cell and gene therapies, the Regenerative Medicine Market faces considerable challenges in terms of manufacturing and scalability. The fragile nature of the biological components used adds to the challenge, resulting in higher expenses and limited patient access.

Furthermore, the high expense of these therapies limits patient access and puts pressure on healthcare systems. The immature reimbursement policies and the unwillingness of insurance companies to cover the costs considering high upfront expenditures and short-term data of regenerative medicine are key challenges limiting its adoption.

Category-Wise Acumens

Will Prevalence Of Chronic Diseases Upsurge Application of Cell Therapy?

According to VMR, the cell therapy segment is estimated to hold the largest market share in the Regenerative Medicine Market during the forecast period. The targeted therapeutic potential, versatility, and personalized approach are features anticipated to boost the expansion of the market. The expansion and dominance of cell therapy in this rapidly evolving market are further propelled by the compliance of simplified and advanced procedures with a favorable regulatory environment is bolstering the use of cell therapy. In addition to this, the growing aging population susceptible to various diseases is resulting in an increase in healthcare cost, thereby demanding affordable regenerative medicines like cell therapies.

The versatility of cell therapies in treating a wide range of ailments, from cancer and autoimmune disorders to neurological and cardiovascular conditions, expands their market reach and potential impact, contributing to the segment's dominant position. Also, cell therapies differ from conventional pharmaceuticals as they adopt a focused approach to illness therapy, minimizing systemic effects and increasing efficacy while minimizing negative effects.

Furthermore, improvements in cell culture and manufacturing processes contribute toward enhancing the efficiency and scalability of cell therapy production, thereby resulting in higher accessibility and cost-effectiveness. Such technological advancements serve as an important role in bolstering the cell therapy segment in the Regenerative Medicine Market.

Which Factors Enhance the Use of Regenerative Medicine in Musculoskeletal Problems?

The musculoskeletal disorders segment is estimated to dominate in the Regenerative Medicine Market over the period. The high prevalence of this disease is creating a substantial demand for treatment options. Also, active research and development efforts have resulted in an efficient process of new cell and gene therapy applicants, firmly establishing musculoskeletal disorders as a dominant segment in the Regenerative Medicine Market.

Arthritis, osteoarthritis, sports injuries, and back discomfort affect a large proportion of the global population. The prevalence of musculoskeletal problems results in a sizable and expanding patient population, producing a high demand for effective treatment alternatives. As a result, the Regenerative Medicine Market has naturally oriented toward tackling the most common difficulties related to musculoskeletal disorders influencing the demand for regenerative medicine.

Furthermore, the high ailments associated with musculoskeletal diseases are spurring the demand for innovative treatments to relieve symptoms for providing long-term benefits. Thus, regenerative medicine therapies, with their ability to promote tissue repair and regeneration, offer a promising option for treating the underlying causes of many illnesses. This advantage is likely to enable the musculoskeletal disorder segment to dominate the market.

Country/Region-wise Acumens

How will Well-established Healthcare Infrastructure in North America Drive Regenerative Medicine Market?

According to VMR Analyst, North America is estimated to dominate the Regenerative Medicine Market during the forecast period. The dominance of this segment is attributable to the growing demand for personalized medicine with high compatibility with the current regulatory framework.

Also, the growing number of ailments related to the widespread adoption of social habits such as drinking, smoking, dietary changes, and sedentary lifestyles are leading to an increase in healthcare expenditure. This growing number of diseases among the demographic group, especially the aged population, is stirring the need for accurate and efficient regenerative medicines in the region.

A rising number of people are reaching older age groups, leading to an increased incidence of aging-related chronic disorders in the North American region. Regenerative medicine, with its ability to repair and replace damaged tissues, is ideal for the healthcare needs of an aging population, propelling market growth.

Furthermore, the United States Food and Drug Administration (FDA) established streamlined paths for cell and gene therapy approval, promoting faster regulatory approvals and market access. As a result, North America's advantageous regulatory structure, particularly in the United States, is a key driver of the Regenerative Medicine Market in North America.

What are the Key Drivers Influencing the Adoption of Regenerative Medicine in Asia Pacific?

Asia Pacific is estimated to grow at the highest CAGR in the Regenerative Medicine Market during the forecast period due to the high healthcare spending among large and growing patient populations wanting affordable therapies. This growing focus on using regenerative medicines to treat infectious diseases along with the support and funding of government-driven healthcare initiatives is likely to create a dynamic and developing market landscape with tremendous opportunities for innovation and success in this region.

Individuals and governments are increasingly able to invest in innovative and costly medical technology, such as regenerative medicines. This trend is projected to enable the expansion of the market and facilitate the adoption of innovative treatments in the region, propelling the demand for regenerative medicine.

Furthermore, the frequent occurrence of diseases such as hepatitis and dengue fever increases the demand for effective regenerative therapies in this area. Thus, growing awareness regarding the popularity and potential of regenerative medicine in combating diseases among governments and healthcare organizations in combating infectious diseases, resulting in increased investment and research in this field.

Competitive Landscape

The regenerative medicine sector is a battleground for innovation, with established pharmaceutical giants competing for domination alongside dynamic startups. While large firms have extensive portfolios and established distribution networks, versatile startups provide innovative platforms and individualized treatments. This dynamic landscape offers ongoing evolution and ground-breaking discoveries, delivering an exciting ride for both investors and patients.

Some of the prominent players operating in the Regenerative Medicine Market include:

Johnson & Johnson

Novartis

Roche

AbbVie

Pfizer

Vericel Corporation

Cellular Dynamics International, Editas Medicine

Spark Therapeutics

Bluebird bio

Fate Therapeutics

Autolus Therapeutics

Tmunity Therapeutics

Rocket Pharmaceuticals

Carbios Therapeutics

Regentis

Cellular Bioengineering (CBE) Korea

Athersys Inc.

ReNeuron

Histogenics

Regenerative Medicine Market Latest Developments

In January 2024, Vertex Pharmaceuticals has reported promising Phase 2b data for VX-886, a stem cell therapy for pulmonary fibrosis, showing increased lung function and breathing capacity in patients.

In January 2024, Rocket Pharmaceuticals has initiated a Phase 3 trial for its RVL001 stem cell therapy for alpha-1 antitrypsin deficiency (AATD), a rare genetic liver disease, marking a significant step towards commercialization and providing a potentially life-saving treatment for AATD sufferers.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL REGENERATIVE MEDICINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL REGENERATIVE MEDICINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porter's Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Therapeutics
• 5.3 Cell Therapy
  • 5.3.1 Stem cell Therapy
  • 5.3.2 Cell Transplantations
• 5.4 Stem cell Therapy Products
• 5.5 Cell-based Immunotherapy Products
• 5.6 Gene Therapy
• 5.7 Tissue Engineering

6 GLOBAL REGENERATIVE MEDICINE MARKET, BY THERAPY AREA

• 6.1 Overview
• 6.2 Oncology
• 6.3 Musculoskeletal Disorders
• 6.4 Dermatology & Wound Care
• 6.5 Cardiovascular Diseases
• 6.6 Ophthalmology
• 6.7 Neurology
• 6.8 Other applications

7 GLOBAL REGENERATIVE MEDICINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 The U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 The U.K.
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Argentina
  • 7.5.3 Rest of LATAM
• 7.6 Middle East and Africa
  • 7.6.1 UAE
  • 7.6.2 Saudi Arabia
  • 7.6.3 South Africa
  • 7.6.4 Rest of the Middle East and Africa

8 GLOBAL REGENERATIVE MEDICINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies
• 8.4 Company Regional Footprint
• 8.5 Company Industry Footprint
• 8.6 ACE Matrix

9 COMPANY PROFILES

• 9.1 Johnson & Johnson
  • 9.1.1 Company Overview
  • 9.1.2 Company Insights
  • 9.1.3 Business Breakdown
  • 9.1.4 Product Benchmarking
  • 9.1.5 Key Developments
  • 9.1.6 Winning Imperatives
  • 9.1.7 Current Focus & Strategies
  • 9.1.8 Threat from Competition
  • 9.1.9 SWOT Analysis
• 9.2 Novartis
  • 9.2.1 Company Overview
  • 9.2.2 Company Insights
  • 9.2.3 Business Breakdown
  • 9.2.4 Product Benchmarking
  • 9.2.5 Key Developments
  • 9.2.6 Winning Imperatives
  • 9.2.7 Current Focus & Strategies
  • 9.2.8 Threat from Competition
  • 9.2.9 SWOT Analysis
• 9.3 Roche
  • 9.3.1 Company Overview
  • 9.3.2 Company Insights
  • 9.3.3 Business Breakdown
  • 9.3.4 Product Benchmarking
  • 9.3.5 Key Developments
  • 9.3.6 Winning Imperatives
  • 9.3.7 Current Focus & Strategies
  • 9.3.8 Threat from Competition
  • 9.3.9 SWOT Analysis
• 9.4 AbbVie
  • 9.4.1 Company Overview
  • 9.4.2 Company Insights
  • 9.4.3 Business Breakdown
  • 9.4.4 Product Benchmarking
  • 9.4.5 Key Developments
  • 9.4.6 Winning Imperatives
  • 9.4.7 Current Focus & Strategies
  • 9.4.8 Threat from Competition
  • 9.4.9 SWOT Analysis
• 9.5 Pfizer
  • 9.5.1 Company Overview
  • 9.5.2 Company Insights
  • 9.5.3 Business Breakdown
  • 9.5.4 Product Benchmarking
  • 9.5.5 Key Developments
  • 9.5.6 Winning Imperatives
  • 9.5.7 Current Focus & Strategies
  • 9.5.8 Threat from Competition
  • 9.5.9 SWOT Analysis
• 9.6 Vericel Corporation
  • 9.6.1 Company Overview
  • 9.6.2 Company Insights
  • 9.6.3 Business Breakdown
  • 9.6.4 Product Benchmarking
  • 9.6.5 Key Developments
  • 9.6.6 Winning Imperatives
  • 9.6.7 Current Focus & Strategies
  • 9.6.8 Threat from Competition
  • 9.6.9 SWOT Analysis
• 9.7 Cellular Dynamics International
  • 9.7.1 Company Overview
  • 9.7.2 Company Insights
  • 9.7.3 Business Breakdown
  • 9.7.4 Product Benchmarking
  • 9.7.5 Key Developments
  • 9.7.6 Winning Imperatives
  • 9.7.7 Current Focus & Strategies
  • 9.7.8 Threat from Competition
  • 9.7.9 SWOT Analysis
• 9.8 Editas Medicine
  • 9.8.1 Company Overview
  • 9.8.2 Company Insights
  • 9.8.3 Business Breakdown
  • 9.8.4 Product Benchmarking
  • 9.8.5 Key Developments
  • 9.8.6 Winning Imperatives
  • 9.8.7 Current Focus & Strategies
  • 9.8.8 Threat from Competition
  • 9.8.9 SWOT Analysis
• 9.9 Spark Therapeutics
  • 9.9.1 Company Overview
  • 9.9.2 Company Insights
  • 9.9.3 Business Breakdown
  • 9.9.4 Product Benchmarking
  • 9.9.5 Key Developments
  • 9.9.6 Winning Imperatives
  • 9.9.7 Current Focus & Strategies
  • 9.9.8 Threat from Competition
  • 9.9.9 SWOT Analysis
• 9.10 Bluebird bio
  • 9.10.1 Company Overview
  • 9.10.2 Company Insights
  • 9.10.3 Business Breakdown
  • 9.10.4 Product Benchmarking
  • 9.10.5 Key Developments
  • 9.10.6 Winning Imperatives
  • 9.10.7 Current Focus & Strategies
  • 9.10.8 Threat from Competition
  • 9.10.9 SWOT Analysis

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research